These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1055 related articles for article (PubMed ID: 29548607)

  • 1. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.
    Tete SM; Jul-Larsen Å; Rostami S; Lunde THF; Søland H; Krammer F; Cox RJ
    Vaccine; 2018 Apr; 36(16):2213-2219. PubMed ID: 29548607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
    Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.
    van der Most RG; Clément F; Willekens J; Dewé W; Walravens K; Vaughn DW; Leroux-Roels G
    Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28446441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single dose vaccination of the ASO3-adjuvanted A(H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains.
    Lartey S; Pathirana RD; Zhou F; Jul-Larsen Å; Montomoli E; Wood J; Cox RJ
    Hum Vaccin Immunother; 2015; 11(7):1654-62. PubMed ID: 26009966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.
    Yang WH; Dionne M; Kyle M; Aggarwal N; Li P; Madariaga M; Godeaux O; Vaughn DW
    Vaccine; 2013 Sep; 31(40):4389-97. PubMed ID: 23856331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans.
    Miller MS; Tsibane T; Krammer F; Hai R; Rahmat S; Basler CF; Palese P
    J Infect Dis; 2013 Jan; 207(1):98-105. PubMed ID: 23087428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza viruses and cross-reactivity in healthy adults: humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus.
    Iorio AM; Bistoni O; Galdiero M; Lepri E; Camilloni B; Russano AM; Neri M; Basileo M; Spinozzi F
    Vaccine; 2012 Feb; 30(9):1617-23. PubMed ID: 22245606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection.
    Ahmed MS; Jacques LC; Mahallawi W; Ferrara F; Temperton N; Upile N; Vaughan C; Sharma R; Beer H; Hoschler K; McNamara PS; Zhang Q
    Antiviral Res; 2015 Feb; 114():106-12. PubMed ID: 25513756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
    Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults.
    Ikematsu H; Nagai H; Kawashima M; Kawakami Y; Tenjinbaru K; Li P; Walravens K; Gillard P; Roman F
    Hum Vaccin Immunother; 2012 Feb; 8(2):260-6. PubMed ID: 22426369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-neutralizing antibody responses following A(H1N1)pdm09 influenza vaccination with or without AS03 adjuvant system.
    Friel D; Co M; Ollinger T; Salaun B; Schuind A; Li P; Walravens K; Ennis FA; Vaughn DW
    Influenza Other Respir Viruses; 2021 Jan; 15(1):110-120. PubMed ID: 32889792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine-associated enhanced respiratory disease does not interfere with the adaptive immune response following challenge with pandemic A/H1N1 2009.
    Gauger PC; Loving CL; Lager KM; Janke BH; Kehrli ME; Roth JA; Vincent AL
    Viral Immunol; 2013 Oct; 26(5):314-21. PubMed ID: 24033080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans.
    Nachbagauer R; Wohlbold TJ; Hirsh A; Hai R; Sjursen H; Palese P; Cox RJ; Krammer F
    J Virol; 2014 Nov; 88(22):13260-8. PubMed ID: 25210189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influenza A haemagglutinin specific IgG responses in children and adults after seasonal trivalent live attenuated influenza vaccination.
    Islam S; Mohn KG; Krammer F; Sanne M; Bredholt G; Jul-Larsen Å; Tete SM; Zhou F; Brokstad KA; Cox RJ
    Vaccine; 2017 Oct; 35(42):5666-5673. PubMed ID: 28899626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines.
    Hauser MI; Muscatello DJ; Soh ACY; Dwyer DE; Turner RM
    Vaccine; 2019 Jul; 37(31):4246-4255. PubMed ID: 31253447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies.
    Faenzi E; Zedda L; Bardelli M; Spensieri F; Borgogni E; Volpini G; Buricchi F; Pasini FL; Capecchi PL; Montanaro F; Belli R; Lattanzi M; Piccirella S; Montomoli E; Ahmed SS; Rappuoli R; Del Giudice G; Finco O; Castellino F; Galli G
    Vaccine; 2012 Jun; 30(27):4086-94. PubMed ID: 22521851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.
    Poder A; Simurka P; Li P; Roy-Ghanta S; Vaughn D
    Vaccine; 2014 Feb; 32(9):1121-9. PubMed ID: 24252703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-existing immunity with high neutralizing activity to 2009 pandemic H1N1 influenza virus in Shanghai population.
    Liu X; Liu Y; Zhang Y; Chen Z; Tang Z; Xu Q; Wang Y; Zhao P; Qi Z
    PLoS One; 2013; 8(3):e58810. PubMed ID: 23527030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.
    Caillet C; Piras F; Bernard MC; de Montfort A; Boudet F; Vogel FR; Hoffenbach A; Moste C; Kusters I
    Vaccine; 2010 Apr; 28(18):3076-9. PubMed ID: 20193791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.